Clinical Trial: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Brief Summary: Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
Detailed Summary:
Sponsor: Walter Reed Army Medical Center
Current Primary Outcome: Adverse Events (Ocular and Systemic) [ Time Frame: 24 weeks ]
Original Primary Outcome:
Current Secondary Outcome: Size and Extent of Corneal Neovascularization [ Time Frame: 24 weeks ]
Original Secondary Outcome:
Information By: Walter Reed Army Medical Center
Dates:
Date Received: August 6, 2007
Date Started: August 2007
Date Completion:
Last Updated: July 3, 2013
Last Verified: July 2013